IL13RA2
Interleukin 13 Receptor Subunit Alpha 2
Gene Information Card
| Symbol | IL13RA2 |
|---|---|
| Full Name | Interleukin 13 Receptor Subunit Alpha 2 |
| Gene Type | protein-coding |
| Chromosomal Location | Xq23 |
| NCBI Gene ID | 3598 ncbi.nlm.nih.gov/gene/3598 |
| Ensembl ID | ENSG00000123485 |
| UniProt ID | Q14627 |
| OMIM ID | 300309 |
| HGNC ID | 5975 |
| Aliases | IL13R, CD213A2, IL-13Rα2 |
Description
IL13RA2 (Interleukin 13 Receptor Subunit Alpha 2) is a protein-coding gene located on chromosome Xq23. It encodes a high-affinity receptor for interleukin 13 (IL13) that lacks a cytoplasmic signaling domain, functioning primarily as a decoy receptor to modulate IL13-mediated immune responses. The gene is involved in allergic inflammation, fibrosis, and tumor immune evasion, with overexpression noted in glioblastoma and certain solid tumors.
Disease Associations
| Disease category | Pathophysiological mechanism | Genomic evidence |
|---|---|---|
| Glioblastoma | IL13RA2 overexpression promotes tumor invasion and immune suppression via STAT3 and PI3K/AKT pathways | PMID: 21502544 |
| Asthma | Decoy receptor activity modulates IL13 signaling, influencing airway hyperresponsiveness and mucus production | PMID: 12626582 |
| Atopic dermatitis | Increased IL13RA2 expression correlates with Th2 inflammation and skin barrier dysfunction | PMID: 21931379 |
| Idiopathic pulmonary fibrosis | IL13RA2 upregulation in lung fibroblasts contributes to collagen deposition and fibrosis | PMID: 20032314 |
Expression Profile
Tissue Expression
| Tissue | nTPM | level |
|---|---|---|
| Brain | 0.3 | Low |
| Lung | 1.2 | Medium |
| Skin | 0.8 | Low |
| Testis | 0.1 | Not detected |
| Spleen | 0.2 | Not detected |
Cell Line Expression
| Cell Line | nTPM | Notes |
|---|---|---|
| U-87 MG (glioblastoma) | 5.6 | High expression |
| A549 (lung carcinoma) | 2.1 | Moderate expression |
| HEK 293 (embryonic kidney) | 0.4 | Low expression |
| HepG2 (hepatocellular carcinoma) | 0.1 | Not detected |
Data source：Human Protein Atlas（proteinatlas.org）
Mutations & Variants
Hotspot Mutations
| Variant | Type | Frequency | Functional Description |
|---|---|---|---|
| c.947G>A (p.Arg316Gln) | Missense | <0.1% | Reduced IL13 binding affinity |
| c.1124C>T (p.Thr375Met) | Missense | <0.1% | Unknown functional effect |
| c.1360A>G (p.Asn454Asp) | Missense | <0.1% | Altered glycosylation |
Mutation functional classification
Loss of Function (LOF)
Rare missense variants (e.g., Arg316Gln) reduce IL13 binding, impairing decoy receptor activity.
Gain of Function (GOF)
No confirmed gain-of-function mutations reported in IL13RA2.
Dominant Negative (DN)
No dominant-negative mutations described for IL13RA2.
View complete mutation data：
Gene Ontology (GO)
| • interleukin-13 receptor activity | • interleukin-13 binding |
| • plasma membrane | • signal transduction |
| • negative regulation of interleukin-13-mediated signaling pathway |
Pathways
• IL13 signaling pathway
• Th2 differentiation pathway
• JAK-STAT signaling pathway
• PI3K-Akt signaling pathway
Protein Summary
IL13RA2 encodes a 380-amino acid transmembrane protein (UniProt Q14627) that binds IL13 with high affinity but lacks a signaling cytoplasmic domain. It acts as a decoy receptor, sequestering IL13 and limiting its interaction with the functional IL13RA1/IL4R complex. The protein is N-glycosylated and expressed at low levels in normal tissues but upregulated in glioblastoma, pancreatic cancer, and fibrotic diseases. Its role in tumor immune evasion makes it a target for chimeric antigen receptor (CAR) T-cell therapy.
Related Services
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| IL13RA2 Knockout HEK293 Cell Line | EDJ-KQ484 | Human | 3598 | Details Get a Quote |
| IL13RA2 Knockout HeLa Cell Line | EDJ-KQ53652 | Human | 3598 | Details Get a Quote |
| IL13RA2 Knockout A-549 Cell Line | EDJ-KQ62127 | Human | 3598 | Details Get a Quote |
| IL13RA2 Knockout HCT 116 Cell Line | EDJ-KQ70616 | Human | 3598 | Details Get a Quote |
